Immune Checkpoint Blockade - 30/05/14
, David B. Page, MD a, Jedd D. Wolchok, MD, PhD b, cRésumé |
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs. Several antibodies are now in development, aimed at blocking novel immune checkpoint molecules, such as PD-1 and it’s corresponding ligand PD-L1. This article summarizes the mechanism of action, preclinical development, and subsequent clinical studies of immune checkpoint antibodies in melanoma.
Le texte complet de cet article est disponible en PDF.Keywords : Ipilimumab, Tremelimumab, Nivolumab, Immunotherapy, Checkpoint inhibitor, Anti–PD-1, Anti–PD-L1, Anti-CTLA4
Plan
| Disclosures: None. |
|
| Conflicts of Interest: None (J. Naidoo, D.B. Page); Consultant to MedImmune, Merck, GlaxoSmithKline and Bristol Myers-Squibb (J.D. Wolchok). |
Vol 28 - N° 3
P. 585-600 - juin 2014 Retour au numéro
Article précédent
- Interferon, Interleukin-2, and Other Cytokines
- Elizabeth I. Buchbinder, David F. McDermott
- Combinatorial Approach to Treatment of Melanoma
- Michelle T. Ashworth, Adil I. Daud
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?